Results 171 to 180 of about 4,245 (206)
Some of the next articles are maybe not open access.
Lung Cancer, 2020
Peptide receptor radionuclide therapy (PRRT) has been proven to be effective in gastro-entero-pancreatic neuroendocrine tumours (NETs) using 90Yttrium (90Y)- or 177Lutetium (177Lu)-based somatostatin peptides, with 177Lu-DOTATATE recently licensed.
Eitan Mirvis +5 more
openaire +2 more sources
Peptide receptor radionuclide therapy (PRRT) has been proven to be effective in gastro-entero-pancreatic neuroendocrine tumours (NETs) using 90Yttrium (90Y)- or 177Lutetium (177Lu)-based somatostatin peptides, with 177Lu-DOTATATE recently licensed.
Eitan Mirvis +5 more
openaire +2 more sources
European Journal of Nuclear Medicine and Molecular Imaging, 2018
Rectal neuroendocrine neoplasia (NEN) is more common than other NEN origins, but is less commonly metastatic. However, when present, distant disease carries a particularly poor prognosis. Evidence guiding optimal treatment of such patients is lacking. We assessed PRRT outcomes in patients with somatostatin receptor (SSTR) positive metastatic rectal NEN
Grace Kong +10 more
openaire +2 more sources
Rectal neuroendocrine neoplasia (NEN) is more common than other NEN origins, but is less commonly metastatic. However, when present, distant disease carries a particularly poor prognosis. Evidence guiding optimal treatment of such patients is lacking. We assessed PRRT outcomes in patients with somatostatin receptor (SSTR) positive metastatic rectal NEN
Grace Kong +10 more
openaire +2 more sources
Journal of Clinical Oncology, 2020
e16700 Background: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is an innovative treatment for inoperable or metastasized, well/moderately differentiated, neuroendocrine tumors (NETs). Currently PRRT cannot be performed in Japan, because there is no approval and insurance cover until now.
Kobayashi, Noritoshi +3 more
openaire +2 more sources
e16700 Background: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is an innovative treatment for inoperable or metastasized, well/moderately differentiated, neuroendocrine tumors (NETs). Currently PRRT cannot be performed in Japan, because there is no approval and insurance cover until now.
Kobayashi, Noritoshi +3 more
openaire +2 more sources
Seminars in Nuclear Medicine, 2016
As therapeutic options in advanced medullary and non-iodine avid differentiated (nonmedullary) thyroid cancers are limited and associated with significant toxicity, targeting of somatostatin receptors (SSTRs) for internal radiation therapy provides a promising option.
Ali, Salavati +4 more
openaire +2 more sources
As therapeutic options in advanced medullary and non-iodine avid differentiated (nonmedullary) thyroid cancers are limited and associated with significant toxicity, targeting of somatostatin receptors (SSTRs) for internal radiation therapy provides a promising option.
Ali, Salavati +4 more
openaire +2 more sources
Journal of Clinical Oncology, 2017
e15694 Background:Grade 3 (G3) NETs have a poor prognosis and limited treatment options (usually chemotherapy). PRRT is a potential treatment option if all sites of disease demonstrate high uptake on somatostatin-receptor imaging (SSRI). We retrospectively evaluated the efficacy of PRRT in G3 NETs.
Mei Sim Lung +5 more
openaire +1 more source
e15694 Background:Grade 3 (G3) NETs have a poor prognosis and limited treatment options (usually chemotherapy). PRRT is a potential treatment option if all sites of disease demonstrate high uptake on somatostatin-receptor imaging (SSRI). We retrospectively evaluated the efficacy of PRRT in G3 NETs.
Mei Sim Lung +5 more
openaire +1 more source
Endocrine, 2014
We report on a 70-year-old man affected by radioiodine-refractory differentiated thyroid cancer (DTC) in whom metastases were treated by peptide receptor radionuclide therapy (PRRT). Seven years before, patient had undergone total thyroidectomy. Pathological examination was conclusive for DTC.
CAMPENNI', Alfredo +2 more
openaire +3 more sources
We report on a 70-year-old man affected by radioiodine-refractory differentiated thyroid cancer (DTC) in whom metastases were treated by peptide receptor radionuclide therapy (PRRT). Seven years before, patient had undergone total thyroidectomy. Pathological examination was conclusive for DTC.
CAMPENNI', Alfredo +2 more
openaire +3 more sources
Peptide Receptor Radionuclide Therapy (PRRT): clinical Application
2015Neuroendocrine tumors are generally slow growing and are frequently discovered when metastatic spread has occurred. This leaves room for multiple treatments, individualized through a multidisciplinary approach that considers tumor type, extension, and related symptoms.
Bodei, Lisa, PAGANELLI, Giovanni
openaire +1 more source
European Journal of Nuclear Medicine and Molecular Imaging
We performed a systematic review and meta-analysis to investigate the efficacy of peptide receptor radionuclide therapy (PRRT) by using radiolabeled somatostatin analogues in high grade gastro-entero-pancreatic neoplasms (GEP-NEN).All clinical studies published up to March 2025, including patients with grade 3 (G3) GEP-NEN treated with [177Lu] Lu-DOTA ...
Zampella, Emilia +9 more
openaire +4 more sources
We performed a systematic review and meta-analysis to investigate the efficacy of peptide receptor radionuclide therapy (PRRT) by using radiolabeled somatostatin analogues in high grade gastro-entero-pancreatic neoplasms (GEP-NEN).All clinical studies published up to March 2025, including patients with grade 3 (G3) GEP-NEN treated with [177Lu] Lu-DOTA ...
Zampella, Emilia +9 more
openaire +4 more sources
Pretherapy Prediction of Nephrotoxicity After Peptide Radionuclide Receptor Therapy (PRRT)
Cancer Biotherapy and Radiopharmaceuticals, 2010Gerald L, Denardo, Daniel J, Macey
openaire +2 more sources
Peptide receptor radionuclide therapies (PRRTs): Which are the dosimetric data for the patients?
Physica Medica, 2014A.P. Stefanoyiannis +9 more
openaire +1 more source